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1684-1182/Copyright ª 2015, TaiwanAbstract Background/purpose: Although patients suffering community-acquired perforated
peptic ulcer (PPU)-associated peritonitis with Candida species isolated from their peritoneal
fluid have higher chances of mortality and experiencing a complicated postoperative clinical
course, universal antifungal therapy for these patients remains controversial.
Methods: This is a retrospective analysis of the impacts of antifungal therapy on outcomes of
patients suffering community-acquired PPU-associated peritonitis with Candida species iso-
lated from their ascites at a medical center in Taiwan. All included patients received source
control and antibiotic treatment, with or without additional postoperative antifungal therapy
with fluconazole or an echinocandin for at least 3 days.
Results: Among the 133 included patients, 76 did not receive (Group 1) and 57 did receive
(Group 2) antifungal therapy. Sixteen (12%) of the overall included patients died within 30
days. Shock [odds ratio (OR), 5.6; 95% confidence interval (CI), 1.9e16.5; pZ 0.002] and high-
er Acute Physiology and Chronic Health Evaluation II score (>20; OR, 9.5; 95% CI, 1.1e80.7;
p Z 0.04) were independently associated with 30-day mortality. Among the 80 matched pa-
tients from Groups 1 and 2 (1:1 matched) with the closest propensity score, no significant dif-
ference was found in 30-day all-cause mortality, time to mortality, the need for reoperation/fection Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta
g 833, Taiwan.
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fluid, Journal of Microbiology, Immuabscess formation/anastomotic leakage, prolonged intensive care unit stay, and prolonged me-
chanical ventilator dependence between patients with and without antifungal therapy.
Conclusion: Our study provides solid evidence supporting the notions that antifungal therapies
do not benefit patients suffering PPU peritonitis with Candida species isolated from their asci-
tes in general, and antifungal therapy could be reserved for patients who are critically ill and/
or severely immunocompromised.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
It has been well documented that candidemia causes sub-
stantial mortality, and thus, initiating necessary antifungal
therapy in the initial stages of the infection is necessary to
lower the mortality rate in these patients.1 Although
isolation of Candida species from patients with intra-
abdominal infections was reported to be associated with
an increase in mortality and a complicated postoperative
course,2e6 antifungal agents prescribed in these scenarios
are still controversial. Antifungal therapy is recommended
for treatment of peritonitis with Candida isolation in peri-
toneal fluid for patients who acquired the infection from
hospital settings,4 staying at an intensive care unit (ICU)
and with recurrent peptic ulcer,5,7 as well as for those who
are critically ill and/or severely immunocompromised.2,7,8
However, when it comes to peritonitis resulting from
perforated peptic ulcer (PPU) involving the upper gastro-
intestinal tract with the isolation of Candida species from
ascites, there is no consensus yet on whether or not an
antifungal agent should be added to antibiotic therapy. The
Surgical Infection Society and the Infectious-Diseases Soci-
ety of America recommends antifungal treatment for
community-acquired intra-abdominal infections in only
clinically severe cases.7 However, these recommendations
were not made based on any solid research evidence.7,8 To
clarify the role of antifungal therapy for patients suffering
community-acquired PPU-associated peritonitis with
Candida species isolated from their ascites, we performed a
retrospective study analyzing this patient population at a
large medical center in Taiwan.Methods
Study design, patients, and Candida isolates
This is a retrospective study conducted at Kaohsiung Chang
Gung Memorial Hospital (KCGMH), a 2700-bed facility
serving as a primary care and tertiary referral center in
Southern Taiwan. Included patients were adults (agedS 18
years) hospitalized between January 2008 and December
2012 with a PPU diagnosed within 48 hours upon their
arrival and a subsequent growth of Candida species from
their ascites sampled during surgical operation. De-
mographic, clinical, and laboratory information of the
included patients was retrieved from their medical records
at chart review. This study was approved by thei W-S, et al., Antifungal therapy
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nology and Infection (2015), http:Institutional Review Board of Chang Gung Memorial Hospital
with a waiver of patient consent (Document No. 103-
4156B).
The collected ascites were inoculated on a blood agar
medium for incubation. If colonies that grew were micro-
scopically found to be yeast-like organisms, they were
identified as a Candida species by inoculation on a Sabo-
uraud dextrose agar, inhibitory mold agar, Mycosel agar,
and braineheart infusion agar media with 10% sheep blood
(Becton-Dickinson Microbiology System, Becton Dickinson,
MD, USA), in accordance with standard methods prescribed
for Candida culture.9 The identification to species level for
a Candida was carried out using either CHROMagar Candida
(CHROMagar, Paris, France) or API-ID 32C (bioMe´rieux
VITEK, Hazelwood, MO, USA) only under the request of the
physicians.
Definitions
After the diagnosis of PPU was made, all included patients
received an immediate empirical antibiotic therapy, and a
surgical operation was performed within the next 12 hours.
The patient’s physician decided whether or not to initiate
additional antifungal therapy. If antifungal agents were
used on either an empirical or a definitive basis, they were
started only after the operation. All antifungal therapies
administered were considered appropriate, as either flu-
conazole or an echinocandin (micafungin, anidulafungin, or
caspofungin) was used for at least 3 days.10,11 All Candida
species recently isolated at KCGMH were found to be sus-
ceptible to both fluconazole and echinocandins (data not
shown).
Variables included for analysis were age, body mass
index, sex, underlying diseases/conditions, preoperative
clinical manifestations and laboratory data, appropriate-
ness of antibiotic therapy, and adequacy of infection source
control. Specifically, underlying diseases/conditions
included heavy alcohol drinking (men consumed> 30 g
alcohol/d, whereas women consumed > 15 g alcohol/d, for
S1 year),12 liver cirrhosis (diagnosed by abdominal sonog-
raphy),13 type 2 diabetes mellitus,14 chronic kidney disease
[estimated glomerular filtration rate (eGFR) < 60 mL/min/
1.73 m2],15 solid tumors, hematologic diseases, high-dose
steroid use (S20 mg prednisolone daily for >3 weeks),16
and receipt of organ transplantation. Antibiotic therapy
was considered suboptimal when (1) the empirically pre-
scribed antibiotic(s) was (were) not in accordance with the
principles of antibiotic use for intra-abdominal infectiondid not improve outcomes including 30-day all-cause mortality in
ted peritonitis with Candida species isolated from their peritoneal
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as judged by an infectious diseases specialist,17 and/or (2)
for definitive treatment, the pathogenic microbes were
resistant to the prescribed antibiotic(s). An inadequate
source control for a patient with PPU included the post-
operative findings of (1) persistent sepsis in the absence of
other infection focus (e.g., pneumonia and/or catheter-
related infection), (2) persistent contraindications for oral
feeding or enteral feeding through a nasogastric tube
indwelled for 1 week or more, and/or (3) fluid accumula-
tion, pus formation, or anastomotic leakage disclosed by
abdominal computed tomography (CT) and/or during
reoperation. The duration of abdominal pain (in days)
referred to the time lapse from the onset of symptoms to
the patient presenting to our emergency services. Acute
kidney injury was defined as an eGFR below 50% of the
normal range.18 The disease severity was stratified using
Acute Physiology and Chronic Health Evaluation (APACHE) II
scores.19 The primary study endpoint was the 30-day all-
cause mortality rate, and the secondary endpoints
included (1) the presence of intra-abdominal abscess or
anastomotic leakage found by CT and/or during reopera-
tion; (2) ventilator use for 14 days or more after the
operation; and (3) ICU stay for 14 days or more after the
surgery.Statistical analysis
The included patients were divided into the following
groups for analyses: Group 1 and Group 2. Patients in Group
1 did not receive antifungal therapy, whereas those in
Group 2 received antifungal therapy. In univariate analyses
between Groups 1 and 2, the t test or ManneWhitney U test
was used for comparisons of continuous variables, whereas
the c2 test or Fisher exact test was used for comparisons of
dichotomous variables, when appropriate. Variables with a
p value less than 0.1 in univariate analyses were entered
into a multiple logistic regression model to identify inde-
pendent predictor(s) of 30-day mortality. The propensity
score for for patients in both groups described the proba-
bility for including them on the basis of his or her de-
mographic, clinical, and laboratory characteristics. The
estimated propensity scores could then be used either as a
stratification variable or as a controlling variable in a
multivariable model, or it could also be used to derive a
propensity score-matched cohort where all the variables
used to derive the propensity score are balanced.20 Sub-
sequently, patients in Group 1 were matched with those in
Group 2 (1:1 match) with the closest propensity score, and
a maximal difference of 5% in the likelihood of the mor-
tality was allowed in the matching process. If there was
more than one possible match with an identical propensity
score, APACHE II scores (secondary matching variable) were
considered in the matching process. Matched patients were
reanalyzed as described earlier. The 30-day all-cause
mortality rates in these two matched groups were
compared with each other, and time to mortality was
evaluated using the KaplaneMeier curve and log-rank test.
A p value less than 0.05 was considered statistically sig-
nificant. Data were analyzed using the SPSS software for
Windows, version 12.0 (SPSS Inc., Chicago, IL, USA).Please cite this article in press as: Li W-S, et al., Antifungal therapy
patients suffering community-acquired perforated peptic ulcer-associa
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Among the 347 patients with ascites culture being positive
for Candida at KCGMH during the study period, 133 fulfilled
the inclusion criteria and were included for analysis. Of
note, none of the included patients experienced candide-
mia and/or bacteremia; simultaneous bacterial growth
from ascites culture was found in 58 patients included in
this study, and the major isolated bacteria were Strepto-
coccus spp. (44.8%), Escherichia coli (27.6%), and Klebsiella
pneumoniae (24.1%). The 30-day mortality of the 58 pa-
tients with concurrent bacteremic peritonitis was not sig-
nificant different from that of the other 75 patients who
had no concurrent bacteremic peritonitis (15.5% vs. 9.3%,
p Z 0.277).
Among these 133 included patients, 57 (42.8%) received
antifungal therapy. Between Group 1 (NZ 76) and Group 2
(N Z 57), no significant difference was found in de-
mographics, laboratory data, and percentage of suboptimal
antibiotic therapy; however, higher degree of clinical
severity was found among patients in Group 2 than among
those in Group 1, which were reflected by the higher pro-
portions of fever (31.6% vs. 13.2%, p Z 0.01), tachycardia
(71.9% vs. 42.1%, p Z 0.001), shock (38.6% vs. 11.8%,
p < 0.001), acute kidney injury (49.1% vs. 28.9%, pZ 0.02),
and high APACHE II scores (>20 points; 75.4% vs. 40.8%,
p < 0.001; Table 1).
A total of 16 patients (12%) died within 30 days after the
surgery. Risk factors for 30-day crude mortality found in
univariate analyses included the following (Table 2): ma-
lignancy (31.3% vs. 11.1%, p Z 0.04), preoperative fever
(43.8% vs. 17.9%, p Z 0.04), tachycardia (81.3% vs. 51.3%,
pZ 0.02), shock (56.3% vs. 18.8%, pZ 0.002), acute kidney
injury (62.5% vs. 34.2%, p Z 0.03), higher APACHE II score
(>20 points, 93.8% vs. 50.4%, p < 0.001), and not starting
empirical antifungal therapy (7.7% vs. 31.1%, p Z 0.01) as
well as inadequate source control (62.5% vs. 29.9%,
p Z 0.01). In the multivariate analysis, shock [odds ratio
(OR), 5.6; 95% confidence interval (CI), 1.9e16.5;
pZ 0.002] and high APACHE II score (>20; OR, 9.5; 95% CI,
1.1e80.7; p Z 0.04) were independent risk factors for 30-
day crude mortality.
Because clinical severity was independently associated
with the 30-day mortality, 80 patients, 40 from Group 1 and
another 40 Group 2, were matched using propensity score
for the KaplaneMeier survival analysis (Figure 1). All the
patients were matched with less than 1% difference in their
propensity scores. The demographic, clinical, and labora-
tory information of the matched patients is presented in
Table 3. Between patients who received antifungal therapy
and those who did not, no significant differences were
found in 30-day all-cause mortality, time to mortality, the
need for reoperation/abscess formation/anastomotic
leakage, prolonged ICU stay, and prolonged mechanical
ventilator dependence.
Discussion
Patients suffering PPU are destined for development of
peritonitis that requires surgical intervention for source
control and antimicrobial therapy for treating thedid not improve outcomes including 30-day all-cause mortality in
ted peritonitis with Candida species isolated from their peritoneal
//dx.doi.org/10.1016/j.jmii.2015.07.004
Table 1 Demographic, clinical, and laboratory characteristics of patients suffering perforated peptic ulcer with Candida
isolated from their ascites without (Group 1) and with postoperative antifungal therapy (Group 2).
Characteristics Group 1
N Z 76
Group 2
N Z 57
p
Age (y, range) 63 (27e89) 70 (38e88) 0.07
BMI (kg/m2, range) 22.1 (15.1e31.8) 23.3 (13.8e36.0) 0.05
Sex (male) 51 (67.1) 36 (63.2) 0.64
Underlying diseases
Heavy alcohol drinking 8 (10.5) 5 (8.8) 0.74
Liver cirrhosis 4 (5.3) 7 (12.3) 0.21
Diabetes mellitus, type 2 19 (25.0) 18 (31.6) 0.40
Chronic kidney disease 18 (23.7) 14 (24.6) 0.91
Solid tumors 10 (13.2)a 8 (14.0)b 0.88
Hematologic disease 1 (1.3) 0 (0) >0.99
High-dose steroid use 0 (0) 1 (1.8) 0.43
Organ-transplant recipient 0 (0) 1 (1.8) 0.43
Preoperative clinical and laboratory features
Fever S 38C 10 (13.2) 18 (31.6) 0.01
Tachycardia (HR S 100 bpm) 32 (42.1) 41 (71.9) 0.001
Shockc 9 (11.8) 22 (38.6) <0.001
Abdominal pain (d, range)d 1 (0e7) 1 (0e7) 0.46
WBC counts: >10,000/mm3, <3000/mm3, or band form >10% 50 (65.8) 43 (75.4) 0.23
C-reactive protein (mg/L, range) 143.1 (0.3e376.8) 148.7 (0.3e388.0) 0.31
Acute kidney injury 22 (28.9) 28 (49.1) 0.02
High APACHE II scores (>20) 31 (40.8) 43 (75.4) <0.001
Positive growth of bacteria from ascites culture 28 (36.8) 30 (52.6) 0.07
Suboptimal antibiotic therapy 2 (2.6) 4 (7.0) 0.40
a Including hepatocellular carcinoma in three, pancreatic cancer in one, as well as nonsmall cell lung carcinoma, rectal cancer, and
buccal cancer each in two patients.
b Including hepatocellular carcinoma, breast cancer, buccal cancer, cervical cancer each in one, and nonsmall cell lung carcinoma in
four patients.
c MBP < 60 mmHg, SBP < 90 mmHg or inotropic agents being used.
d From symptoms onset to presenting to Emergency Services.
Data presented as n (%), unless stated otherwise.
APACHE IIZ Acute Physiology and Chronic Health Evaluation II; BMIZ body mass index; HRZ heart rate; MBPZ mean blood pressure;
SBP Z systolic blood pressure; WBC Z white blood count.
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polymicrobial infection caused by microbes including bac-
teria and Candida that normally colonize the upper
gastrointestinal tract.7,24,25 The isolation of Candida spe-
cies from ascites of patients with PPU-associated perito-
nitis was reportedly associated with higher mortality rate
in this patient group.3,4 Previously published series that
evaluated the role of antifungal therapy in peritonitis with
Candida species isolated from intraperitoneal fluid
included cases with heterogeneous causes24 and clinical
severities/underlying immunocompromises,2,26 and acqui-
sition of peritonitis from both community and hospital
settings,26,27 and thus, these provided little information
concerning the need for antifungal therapy specifically for
peritonitis resulting from PPU. To our knowledge, this is the
largest series addressing community-acquired PPU-associ-
ated peritonitis with Candida species isolated from intra-
peritoneal fluid.
Major pathogens including Streptococcus spp., E. coli,
and K. pneumoniae isolated from the ascites of our patients
were consistent with pathogens that were previously re-
ported in patients with this infectious entity.2e7,26 Our data
showed that the outcomes of patients with PPU-associatedPlease cite this article in press as: Li W-S, et al., Antifungal therapy
patients suffering community-acquired perforated peptic ulcer-associa
fluid, Journal of Microbiology, Immunology and Infection (2015), http:peritonitis under the source control and antibiotic treat-
ment were not significantly influenced by additional anti-
fungal therapy, but were associated with shock and high
APACHE II scores, which were reflective of the patients’
clinical severity and vulnerability.
To minimize possible confounding(s), our evaluation of
the role played by antifungal therapy in patients with PPU-
associated peritonitis included using a multivariate analysis
model. In addition, propensity score matching reduced
possible potential bias. Limitations of this study include (1)
nonrandomized patient allocation and inevitable missing
data, which are always inherent in a retrospective study,
and (2) the lack of identification of all the species of
Candida isolated from the intraperitoneal fluid, which was
done only at our hospital under the request of the clinician.
Nonetheless, most of the Candida isolates that grew from
the intraperitoneal fluid of patients suffering PPU perito-
nitis are Candida albicans.2e7,26,27 All C. albicans isolates at
KCGMH have been found to be susceptible to fluconazole
and echinocandins (data not shown).
In conclusion, this study provides solid evidence sup-
porting the notions that (1) antifungal therapies do not
benefit patients suffering PPU peritonitis with Candidadid not improve outcomes including 30-day all-cause mortality in
ted peritonitis with Candida species isolated from their peritoneal
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Table 2 Demographic, clinical, and laboratory characteristics of patients who survived and those who died within 30 days
after the operation among patients suffering perforated peptic ulcer with Candida isolated from peritoneal fluid.
Characteristics Deceased patients
N Z 16
Survived patients
N Z 117
p
Age (y, range) 71.5 (55e87) 66 (27e89) 0.11
BMI (kg/m2, range) 22.1 (19.7e30.4) 23 (13.8e36.0) 0.39
Sex (male) 12 (75.0) 75 (64.1) 0.39
Underlying diseases
Heavy alcohol drinking 0 (0) 13 (11.1) 0.37
Liver cirrhosis 1 (6.3) 10 (8.5) >0.99
Diabetes mellitus, type 2 4 (25) 33 (28.2) >0.99
Chronic kidney disease 6 (37.5) 26 (22.2) 0.21
Solid tumors 5 (31.3)a 13 (11.1)b 0.04
Hematologic disease 0 (0) 1 (0.9) >0.99
High-dose steroid use 0 (0) 1 (0.9) >0.99
Organ-transplant recipient 0 (0) 1 (0.9) >0.99
Preoperative clinical and laboratory features
Fever S 38C 7 (43.8) 21 (17.9) 0.04
Tachycardia (HR S 100 bpm) 13 (81.3) 60 (51.3) 0.02
Shockc 9 (56.3) 22 (18.8) <0.01
Abdominal pain (d, range)d 1 (0e7) 1 (0e7) 0.99
WBC counts: >10,000/mm3, <3000/mm3, or band form >10% 12 (75.0) 81 (69.2) 0.78
C-reactive protein (mg/L, range) 176.3 (2.8e320.6) 142.6 (0.3e388.0) 0.96
Acute kidney injury 10 (62.5) 40 (34.2) 0.03
High APACHE II scores (> 20) 15 (93.8) 59 (50.4) <0.01
Positive bacterial growth from ascites 9 (56.3) 49 (41.9) 0.28
Therapeutic modality
Antifungal treatment 10 (62.5) 47 (40.2) 0.09
Definitive therapy 5 (31.3) 38 (32.5) 0.52
Empirical therapy 5 (31.3) 9 (7.7) 0.01
Suboptimal antibiotics 1 (6.3) 5 (4.3) 0.55
Inadequate source control 10 (62.5) 35 (29.9) 0.01
a Including rectal cancer in one, and nonsmall cell carcinoma of the lung in four patients.
b Including breast cancer, cervical cancer, pancreatic cancer, and rectal cancer each in one, hepatocellular carcinoma in four, buccal
cancer in three, and nonsmall cell carcinoma of the lung in two patients.
c MBP < 60 mmHg, SBP < 90 mmHg or inotropic agents were used.
d From symptoms onset to presenting to emergency services.
Data presented as n (%), unless stated otherwise.
APACHE IIZ Acute Physiology and Chronic Health Evaluation II; BMIZ body mass index; HRZ heart rate; MBPZ mean blood pressure;
SBP Z systolic blood pressure; WBC Z white blood count.
Figure 1. KaplaneMeier survival analysis curves for patients (from Groups 1 and 2) matched by propensity score with perforated
peptic ulcer and ascites culture positive for Candida spp. Patients who received antifungal therapy had higher survival probability
on 30 days after the operation, but there were no statistical significances (p Z 0.472).
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Table 3 Demographic, clinical, and laboratory characteristics of the matched patients.
Characteristics Without antifungal therapy
N Z 40
With antifungal therapy
N Z 40
p
Age (y, range) 69 (41e89) 69 (38e88) 0.62
BMI (kg/m2, range) 22.1 (15.2e30.0) 23.0 (13.8e30.1) 0.19
Sex (male) 26 (65.0) 24 (60.0) 0.64
Underlying diseases
Heavy alcohol drinking 4 (10.0) 3 (7.5) >0.99
Liver cirrhosis 1 (2.5) 5 (12.5) 0.20
Diabetes mellitus, type 2 13 (32.5) 13 (32.5) >0.99
Chronic kidney disease 12 (30) 9 (22.5) 0.45
Solid tumors 5 (12.5)a 3 (7.5)b 0.71
Hematologic disease 0 (0) 0 (0) d
High-dose steroid use 0 (0) 1 (2.5) >0.99
Organ-transplant recipient 0 (0) 1 (2.5) >0.99
Preoperative clinical and laboratory features
Fever S 38C 7 (17.5) 10 (25.0) 0.41
Tachycardia (HR S 100 bpm) 23 (57.5) 26 (65.0) 0.49
Shockc 8 (20.0) 11 (27.5) 0.43
Abdominal pain (d, range)d 1 (0e7) 2 (0e7) 0.60
WBC counts: >10,000/mm3, <3000/mm3, or band form >10% 27 (67.5) 29 (72.5) 0.63
C-reactive protein (mg/L, range) 168.0 (4.3e380.8) 129.0 (0.3e388.0) 0.43
Acute kidney injury 15 (37.5) 17 (42.5) 0.65
High APACHE II scores (>20) 26 (65.0) 26 (65.0) >0.99
Positive growth of bacteria from ascites culture 14 (35.0) 16 (40.0) 0.64
Suboptimal antibiotics 1 (2.5) 2 (5.0) >0.99
Outcomes
30-d mortality 6 (15.0) 4 (10.0) 0.45
Reoperation or abscess/leakage within 14 d 1 (2.5) 5 (12.5) 0.20
Prolonged ventilator use (>14 d) 3 (7.5) 8 (20.0) 0.11
Prolonged ICU stay (>14 d) 4 (10.0) 11 (27.5) 0.05
a Including rectal cancer in one, buccal cancer as well as nonsmall cell carcinoma of the lung each in two patients.
b Including hepatocellular carcinoma, breast cancer, and nonsmall cell carcinoma of the lung each in one patient.
c MBP < 60 mmHg, SBP < 90 mmHg or inotropic agents were used.
d From symptoms onset to presenting to emergency services.
Data presented as n (%), unless stated otherwise.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; BMI Z body mass index; HR Z heart rate; ICU Z intensive care unit;
MBP Z mean blood pressure; SBP Z systolic blood pressure; WBC Z white blood count.
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+ MODELspecies isolated from their ascites in general, and (2) the
indication for antifungal therapy could be reserved for
patients who are critically ill and/or severely immuno-
compromised. In addition, our study again underscores the
importance of the conventional therapeutic modality,
which includes effective source control and optimal anti-
biotic therapy for patients with PPU peritonitis acquired
from community setting.Conflicts of interest
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